Sodium–glucose co-transporter 2 inhibitors, also known as SGLT2 inhibitors or ‘flozins’, are a new group of diabetes medicines. SGLT2 inhibitors reduce blood glucose levels by removing excess glucose from the blood into the urine. They are not prescribed on their own, but can be used in combination with other diabetes medicines.